| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2002 | WO2002036597A1 Tricyclic derivatives of indole with antiangiogenic activity |
| 05/10/2002 | WO2002036594A1 Process for the preparation of crystalline n-formimidoyl thienamycin monohydrate (imipenem monohydrate) |
| 05/10/2002 | WO2002036593A1 Indole derivatives as pde5-inhibitors |
| 05/10/2002 | WO2002036592A1 Remedies for arachidonic acid-induced skin diseases |
| 05/10/2002 | WO2002036590A1 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives |
| 05/10/2002 | WO2002036589A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 05/10/2002 | WO2002036588A2 Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis |
| 05/10/2002 | WO2002036587A2 Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
| 05/10/2002 | WO2002036586A1 N-type calcium channel antagonists for the treatment of pain |
| 05/10/2002 | WO2002036584A1 Cholesterol lowering benzo`b! thiophenes and benzo`d! isothiazoles |
| 05/10/2002 | WO2002036582A1 Stable pharmaceutical form of an anticancer drug |
| 05/10/2002 | WO2002036576A1 Phthalazinone derivatives |
| 05/10/2002 | WO2002036573A2 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
| 05/10/2002 | WO2002036572A1 Remedies for extraocular inflammatory diseases |
| 05/10/2002 | WO2002036571A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 05/10/2002 | WO2002036570A1 4-substituted quinolines as antitumor agents |
| 05/10/2002 | WO2002036569A1 N-type calcium channel antagonists for the treatment of pain |
| 05/10/2002 | WO2002036568A1 N-type calcium channel antagonists for the treatment of pain |
| 05/10/2002 | WO2002036567A1 N-type calcium channel antagonists for the treatment of pain |
| 05/10/2002 | WO2002036565A1 Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 05/10/2002 | WO2002036564A1 Sulfonylamino substituted 3-(aminomethylide)-2-indolinones as cell proliferation inhibitors |
| 05/10/2002 | WO2002036563A1 Crystalline forms of fluvastatin sodium |
| 05/10/2002 | WO2002036562A2 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| 05/10/2002 | WO2002036561A1 Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 05/10/2002 | WO2002036560A1 Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis |
| 05/10/2002 | WO2002036558A2 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation |
| 05/10/2002 | WO2002036556A2 Acylaminoalkyl-substituted benzenesulfonamide derivatives |
| 05/10/2002 | WO2002036555A1 Sulfamides as gamma-secretase inhibitors |
| 05/10/2002 | WO2002036554A2 Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis |
| 05/10/2002 | WO2002036553A2 Substituted alkanoic acids |
| 05/10/2002 | WO2002036552A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| 05/10/2002 | WO2002036547A1 Cyclopropanecarboxylic acid amide compounds and medicinal use thereof |
| 05/10/2002 | WO2002036546A2 Alkynyl amides and their therapeutic applications |
| 05/10/2002 | WO2002036543A1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 05/10/2002 | WO2002036542A1 Crystalline forms of venlafaxine hydrochloride |
| 05/10/2002 | WO2002036203A2 Azole containing compositions with enhanced antifungal activity |
| 05/10/2002 | WO2002036202A2 Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid |
| 05/10/2002 | WO2002036175A2 Sustained release device for treating conditions of the joint |
| 05/10/2002 | WO2002036171A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| 05/10/2002 | WO2002036167A1 Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids |
| 05/10/2002 | WO2002036163A2 Novel medicament compositions consisting of tiotropium salts and antihistamines for treating respiratory illnesses |
| 05/10/2002 | WO2002036162A2 Compositions for treatment of ocular neovascularization and neural injury |
| 05/10/2002 | WO2002036157A1 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders |
| 05/10/2002 | WO2002036150A1 Gene-digesting gene and enzyme having vaccine-like effect |
| 05/10/2002 | WO2002036149A2 Methods for obtaining inhibitors of t-cell membrane protein (tirc7) ligand binding and uses thereof |
| 05/10/2002 | WO2002036148A2 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death |
| 05/10/2002 | WO2002036137A1 Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa |
| 05/10/2002 | WO2002036135A2 Compositions for antitumour treatment containing ecteinascidin 743 |
| 05/10/2002 | WO2002036134A1 Pharmaceutical or dietary composition containing a vegetable oil, in particular olive oil, and sitosterol |
| 05/10/2002 | WO2002036133A1 New use |
| 05/10/2002 | WO2002036132A1 Anti-inflammatory and healing medicine based on laminarin sulphate |
| 05/10/2002 | WO2002036131A1 In vivo stimulation of angiogenic activity |
| 05/10/2002 | WO2002036130A1 Veterinary composition for the topical treatment of traumatized or inflamed skin |
| 05/10/2002 | WO2002036129A2 Topical treatment of mastalgia with arometese inhibitors such as androstendione |
| 05/10/2002 | WO2002036128A1 Neuroactive steroid derivatives and methods of use |
| 05/10/2002 | WO2002036127A2 Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes |
| 05/10/2002 | WO2002036125A1 The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache |
| 05/10/2002 | WO2002036124A2 Treatment and method using loratadine and montelukast |
| 05/10/2002 | WO2002036123A2 New treatments for restless legs syndrome |
| 05/10/2002 | WO2002036122A1 Preventive or therapeutic medicines for hepatitis and/or hepatopathy |
| 05/10/2002 | WO2002036121A1 Use of 1-ebio in the treatment of bipolar disorders |
| 05/10/2002 | WO2002036119A1 Δ2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke |
| 05/10/2002 | WO2002036118A2 Heterocyclic derivatives useful as pharmaceutical agents |
| 05/10/2002 | WO2002036116A2 Tripeptidyl peptidase inhibitors |
| 05/10/2002 | WO2002036115A1 Sulphonamides for the treatment of central nervous system diseases |
| 05/10/2002 | WO2002036114A1 Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3 |
| 05/10/2002 | WO2002036113A1 Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) |
| 05/10/2002 | WO2002036111A1 New use of 2-(4-isobutylphenyl)propionic acid |
| 05/10/2002 | WO2002036110A2 Oral self-emulsifying formulations of pyranone protease inhibitors |
| 05/10/2002 | WO2002036109A2 Use of pyridoxamine for the treatment and inhibition of obesity-related complications |
| 05/10/2002 | WO2002036108A2 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 05/10/2002 | WO2002036107A2 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
| 05/10/2002 | WO2002036106A2 Novel medicament compositions based on anticholinergics and corticosteroids |
| 05/10/2002 | WO2002036105A2 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| 05/10/2002 | WO2002036104A2 Inhalative solution formulation containing a tiotropium salt |
| 05/10/2002 | WO2002036103A1 Transdermal drug delivery system with improved water absorbability and adhesion properties |
| 05/10/2002 | WO2002036101A1 Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications |
| 05/10/2002 | WO2002036100A1 Controlled release metformin compositions |
| 05/10/2002 | WO2002036099A1 Controlled release hydrocodone formulations |
| 05/10/2002 | WO2002036098A1 Method and preparation for binding acetaldehyde in saliva, stomach and large intestine |
| 05/10/2002 | WO2002036094A2 Method and dermatological and/or cosmetic composition for inhibiting the adhesion effect of circulating cells |
| 05/10/2002 | WO2002036075A2 Small molecule compositions for binding to hsp90 |
| 05/10/2002 | WO2002036073A2 Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| 05/10/2002 | WO2002036071A2 Method of treating and preventing migraine headaches |
| 05/10/2002 | WO2002036066A2 Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia |
| 05/10/2002 | WO2002035987A2 METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES |
| 05/10/2002 | WO2002035931A1 Hydrophilic polymer blends used for dry cow therapy |
| 05/10/2002 | WO2002028868A8 Thiazine derivatives |
| 05/10/2002 | WO2002022600A3 Chemokine receptor binding heterocyclic compounds |
| 05/10/2002 | WO2002020057A3 Flavoring systems for pharmaceutical compositions and methods of making such compositions |
| 05/10/2002 | WO2002016381A3 Composition and method for inhibiting platelet aggregation |
| 05/10/2002 | WO2002016338A8 Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 05/10/2002 | WO2002014464A3 Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections |
| 05/10/2002 | WO2002012238A3 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
| 05/10/2002 | WO2002011743B1 Treatment of prostate cancer |
| 05/10/2002 | WO2002008200A3 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists |
| 05/10/2002 | WO2002007520A3 Antimicrobial composition useful for the treatment of bovine mastitis |
| 05/10/2002 | WO2002002088A3 Anthelmintic agents for preventing parasitic infections in humans and animals iii |
| 05/10/2002 | WO2001097813A3 Highly concentrated stable meloxicam solutions |
| 05/10/2002 | WO2001097809A3 Method of treating cardiovascular disease using rapamycin |